aducanumab

News

Biogen adds real-world test for Aduhelm to its confirmatory ...

Biogen and partner Eisai have said they will run a large-scale observational study of Alzheimer's drug Aduhelm in the US to build evidence for the drug's efficacy following its controversia

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA staffers defend Aduhelm approval in JAMA editorial

Three FDA figures at the centre of the fallout over the approval Biogen and Eisai's Alzheimer's disease therapy Aduhelm have defended their actions, arguing that to do otherwise would have

News

Amid outcry over Aduhelm price, Biogen says it may consider ...

Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer's therapy Aduhelm – but only if its assumptions on population size and uptake are differe

News

Consumer group seeks resignation of top FDA staffers over Ad...

With the first patient set to receive Biogen's new Alzheimer's drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy about the FDA's approva

News

Closeup of X-ray photography of human brain

And then there were three: another FDA adcomm member quits o...

The fallout over the FDA's decision to approved Biogen's Alzheimer's therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning in protest.

News